IP
HRMY icon

Indivisible Partners’s Harmony Biosciences HRMY Stock Holding History

Indivisible Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$780K Buy
21,431
+829
+4% +$26.2K 0.04% 285
2026
Q1 		$577K Buy
20,602
+1,075
+6% +$35.2K 0.05% 260
2025
Q4 		$731K Buy
+19,527
New +$642K 0.08% 187

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Indivisible Partners's HRMY Position: Q2 2026 in Review

Indivisible Partners increased its Harmony Biosciences (HRMY) stake by 4% in Q2 2026, buying an estimated $26.2K and bringing the position to 21,431 shares worth $780K. The position accounts for 0.04% of the portfolio, ranked #285.

Indivisible Partners first reported a position in HRMY in Q4 2025 and has held it in 3 quarters since. 326 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Indivisible Partners held 21,431 shares of Harmony Biosciences worth $780K as of Q2 2026.
  • Indivisible Partners bought 829 Harmony Biosciences shares in Q2 2026, an estimated $26.2K.
  • Harmony Biosciences made up 0.04% of Indivisible Partners's portfolio in Q2 2026, its #285 holding.
  • Indivisible Partners first reported a position in Harmony Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 326 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Indivisible Partners's 13F filing for Q2 2026, filed 4 Aug 2026.